References
- Maj J, Rogoz Z, Skuza G, Kolodziejczyk K. Antidepressant effects of pramipexole, a novel dopamine receptor agonist. J. Neural. Transm. 104(4–5), 525–533 (1997).
- Maj J, Rogoz Z. Synergistic effect of pramipexole and sertraline in the forced swimming test. Polish J. Pharmacol. 51(6), 471–475 (1999).
- Rogoz Z, Skuza G. Mechanism of synergistic action following co-treatment with pramipexole and fluoxetine or sertraline in the forced swimming test in rats. Pharmacol. Rep. 58(4), 493–500 (2006).
- Lattanzi L, Dell’Osso L, Cassano P et al. Pramipexole in treatment-resistant depression: a 16-week naturalistic study. Bipolar Disord. 4(5), 307–314 (2002).
- Inoue T, Kitaichi Y, Masui T et al. Pramipexole for stage 2 treatment-resistant major depression: an open study. Prog. Neuropsychopharmacol. Biol. Psychiatry 34(8), 1446–1449 (2010).
- Sporn J, Ghaemi SN, Sambur MR et al. Pramipexole augmentation in the treatment of unipolar and bipolar depression: a retrospective chart review. Ann. Clin. Psychiatry 12(3), 137–140 (2000).
- Gupta S, Vincent JL, Frank B. Pramipexole: augmentation in the treatment of depressive symptoms. CNS spectr. 11(3), 172–175 (2006).
- Ostow M. Pramipexole for depression. Am. J. Psychiatry 159(2), 320–321 (2002).
- DeBattista C, Solvason HB, Breen JA, Schatzberg AF. Pramipexole augmentation of a selective serotonin reuptake inhibitor in the treatment of depression. J. Clin. Psychopharmacol. 20(2), 274–275 (2000).
- Corrigan MH, Denahan AQ, Wright CE, Ragual RJ, Evans DL. Comparison of pramipexole, fluoxetine, and placebo in patients with major depression. Depress Anxiety 11(2), 58–65 (2000).
- Cusin C, Iovieno N, Iosifescu DV et al. A randomized, double-blind, placebo-controlled trial of pramipexole augmentation in treatment-resistant major depressive disorder. J. Clin. Psychiatry 74(7), e636–e641 (2013).
- Pae CU, Lim HK, Peindl K et al. The atypical antipsychotics olanzapine and risperidone in the treatment of posttraumatic stress disorder: a meta-analysis of randomized, double-blind, placebo-controlled clinical trials. Int. Clin. Psychopharmacol. 23(1), 1–8 (2008).
- Franco-Chaves JA, Mateus CF, Luckenbaugh DA, Martinez PE, Mallinger AG, Zarate CA Jr. Combining a dopamine agonist and selective serotonin reuptake inhibitor for the treatment of depression: a double-blind, randomized pilot study. J. Affect. Disord. 149(1–3), 319–325 (2013).
- Zarate CA Jr, Payne JL, Singh J et al. Pramipexole for bipolar II depression: a placebo-controlled proof of concept study. Biol. Psychiatry 56(1), 54–60 (2004).
- Goldberg JF, Burdick KE, Endick CJ. Preliminary randomized, double-blind, placebo-controlled trial of pramipexole added to mood stabilizers for treatment-resistant bipolar depression. Am. J. Psychiatry 161(3), 564–566 (2004).
- Mitchell PB, Goodwin GM, Johnson GF, Hirschfeld RM. Diagnostic guidelines for bipolar depression: a probabilistic approach. Bipolar Disord. 10(1 Pt 2), 144–152 (2008).
- Lyoo IK, Yoon S, Kim TS et al. A randomized, double-blind placebo-controlled trial of oral creatine monohydrate augmentation for enhanced response to a selective serotonin reuptake inhibitor in women with major depressive disorder. Am. J. Psychiatry 169(9), 937–945 (2012).
- Khajavi D, Farokhnia M, Modabbernia A et al. Oral scopolamine augmentation in moderate to severe major depressive disorder: a randomized, double-blind, placebo-controlled study. J. Clin. Psychiatry 73(11), 1428–1433 (2012).
- Pae CU, Forbes A, Patkar AA. Aripiprazole as adjunctive therapy for patients with major depressive disorder: overview and implications of clinical trial data. CNS drugs 25(2), 109–127 (2011).
- Bergman J, Miodownik C, Bersudsky Y et al. Curcumin as an add-on to antidepressive treatment: a randomized, double-blind, placebo-controlled, pilot clinical study. Clin. Neuropharmacol. 36(3), 73–77 (2013).
Website
- US FDA. Pramipexole Dihydrochloride. www.accessdata.fda.gov/scripts/cder/drugsatfda/ ( Accessed 10 September 2013)